Edition:
India

Soligenix Inc (SNGX.OQ)

SNGX.OQ on NASDAQ Stock Exchange Capital Market

1.98USD
8:37pm IST
Change (% chg)

$0.06 (+3.12%)
Prev Close
$1.92
Open
$1.90
Day's High
$1.98
Day's Low
$1.90
Volume
21,138
Avg. Vol
12,537
52-wk High
$5.07
52-wk Low
$1.77

Chart for

About

Soligenix, Inc. is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical... (more)

Overall

Beta: 2.19
Market Cap(Mil.): $13.11
Shares Outstanding(Mil.): 5.72
Dividend: --
Yield (%): --

Financials

BRIEF-‍Knoll Capital Management LP​ reports a 9.9 pct passive stake in Soligenix as of Nov 2

* ‍Knoll Capital Management LP​ reports a 9.9 percent passive stake in Soligenix Inc as of Nov 2 - SEC Filing Source text: [http://bit.ly/2zVA43d] Further company coverage:

14 Nov 2017

BRIEF-‍ACT Capital Management reports 9.9 pct passive stake in Soligenix - SEC filing​

* ‍act Capital Management LLLP reports 9.9 percent passive stake in Soligenix Inc as of November 2, 2017 - SEC filing​ Source text: (http://bit.ly/2yFcZRO) Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

08 Nov 2017

BRIEF-Soligenix reports Q3 loss per share $0.17

* Soligenix announces recent accomplishments and third quarter 2017 financial results

06 Nov 2017

BRIEF-Soligenix Inc announces pricing of offering

* Soligenix announces pricing of $5,115,000 concurrent registered direct offering and private placement of common stock priced above market

31 Oct 2017

BRIEF-Soligenix receives $1.5 mln to support Phase 3 clinical trial of SGX301​

* Soligenix - ‍national Institutes of Health awarded co about $1.5 million over 2 years to support conduct of pivotal Phase 3 clinical trial evaluating SGX301​ Source text: (http://bit.ly/2yemsz3) Further company coverage:

30 Sep 2017

BRIEF-Soligenix announces $1.5 mln NIDCR SBIR grant award supporting the pivotal phase 3 clinical trial of SGX942

* Soligenix announces $1.5 million NIDCR SBIR grant award supporting the pivotal phase 3 clinical trial of SGX942 for the treatment of oral mucositis in head and neck cancer Source text for Eikon: Further company coverage:

20 Sep 2017

BRIEF-Soligenix announces $1.5 mln NCI SBIR grant award supporting the phase 3 clinical trial of SGX301 for the treatment of cutaneous t-cell lymphoma

* Soligenix announces $1.5 million NCI SBIR grant award supporting the pivotal phase 3 clinical trial of SGX301 for the treatment of cutaneous t-cell lymphoma Source text for Eikon: Further company coverage:

18 Sep 2017

BRIEF-Soligenix receives $2.5 mln in additional Niaid funding to advance development of heat stable ricin vaccine

* Soligenix receives $2.5m in additional Niaid funding to advance development of heat stable ricin vaccine

14 Aug 2017

BRIEF-Soligenix reports Q2 loss per share $0.41

* Soligenix announces recent accomplishments and second quarter 2017 financial results

11 Aug 2017

BRIEF-Soligenix Inc initiates pivotal phase 3 clinical trial of SGX942

* Soligenix initiates pivotal phase 3 clinical trial of sgx942 (dusquetide) for the treatment of oral mucositis in head and neck cancer patients

27 Jul 2017

Earnings vs. Estimates